Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC
Open Access
- 8 May 2025
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (5)
Abstract
Background: The phase 3 DESTINY-Breast04 trial demonstrated superior efficacy and acceptable safety with trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy in previously treated patients with human epidermal growth factor receptor 2 (HER2)–low metastatic breast cancer (mBC). We report the patient-reported outcomes (PROs), focusing on the hormone receptor–positive cohort. Patients and Methods: Patients were randomized 2:1 to T-DXd (5.4 mg/kg intravenously every 3 weeks) or physician’s choice of chemotherapy and prospectively assessed for PRO measures. Change from baseline and time to definitive deterioration (TDD) were calculated from the EORTC QLQ-C30 and QLQ-BR45 and the EQ-5D-5L questionnaires. Results: Baseline global health status/quality of life (GHS/QoL) scores were similar between groups (T-DXd, 331 patients; physician’s choice, 163 patients); there were no clinically meaningful changes while on either treatment (median duration: T-DXd, 8.2 months; physician’s choice, 3.5 months). Median TDD for GHS/QoL was delayed with T-DXd vs physician’s choice (11.4 vs 7.5 months, respectively; hazard ratio, 0.69; 95% CI, 0.52-0.92). Median TDD for all prespecified PROs, including pain, favored T-DXd. In an additional analysis, the median TDD was shorter for nausea and vomiting with T-DXd vs the physician’s choice. Conclusions: Trastuzumab deruxtecan maintained GHS/QoL scores despite a longer treatment course compared with standard chemotherapy and delayed definitive deterioration across all prespecified PROs vs the physician’s choice. Appropriate management of adverse events and use of preventive measures (ie, antiemetic prophylaxis) may further support patient health-related quality of life. These findings reinforce the benefit of T-DXd as an option for patients with HER2-low mBC. ClinicalTrials.gov: NCT03734029Keywords
Funding Information
- Daiichi Sankyo, Inc
- AstraZeneca.
- Daiichi Sankyo, Inc
This publication has 40 references indexed in Scilit:
- Treatment‐associated toxicities reported by patients with early‐stage invasive breast cancerCancer, 2017
- Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)American Society of Clinical Oncology Educational Book, 2016
- Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancerOncoTargets and Therapy, 2016
- Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety AnalysisJournal of Clinical Oncology, 2014
- Treatment of metastatic breast cancer: second line and beyondAnnals of Oncology, 2010
- The Association of Depression and Pain with Health-Related Quality of Life, Disability, and Health Care Use in Cancer PatientsJournal of Pain and Symptom Management, 2010
- Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting and Impact on Functional Quality of Living During Recovery in Patients with High Emetic Risks: A Prospective, Randomized, Double-Blind Comparison of Two Prophylactic Antiemetic RegimensAnesthesia & Analgesia, 2008
- The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group.1998
- Interpreting the significance of changes in health-related quality-of-life scores.Journal of Clinical Oncology, 1998
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993